N🟁N

CryoPort Appoints Cold Chain Shipping Expert Rafik Bishara to its Advisory Board

  //house-home.news-articles.net/content/2011/08/2 .. -expert-rafik-bishara-to-its-advisory-board.html
  Published in House and Home on Monday, August 22nd 2011 at 5:16 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

SAN DIEGO--([ BUSINESS WIRE ])--CryoPort, Inc. (OTCBB: CYRX) today announced that it has retained Rafik H. Bishara, Ph.D., to advise the Company on its business development initiatives, technology programs and overall strategic planning. Dr. Bishara is the current Chair of the Pharmaceutical Cold Chain Interest Group (PCCIG), Parenteral Drug Association (PDA) and is considered one of the worlda™s leading experts in cold chain distribution and shipping of pharmaceutical products and life science materials.

"As we gain commercial momentum, Dr. Bishara will play a key role in many areas, including identifying new market opportunities, expanding industry awareness of the CryoPort Express® Dry Shipping solution, and demonstrating the advantages of adopting our services and product technology."

aRafik Bishara is the life science industrya™s most prominent voice for improving cold chain shipping, and developing regulatory guidelines and standards for transporting pharmaceutical and biotech products,a said Larry Stambaugh, CryoPorta™s Chairman and Chief Executive Officer. aAs we gain commercial momentum, Dr. Bishara will play a key role in many areas, including identifying new market opportunities, expanding industry awareness of the CryoPort Express^® Dry Shipping solution, and demonstrating the advantages of adopting our services and product technology.a

aCryoPorta™s shipper and ordering system represent a significant advancement in deep frozen shipping,a said Dr. Bishara. aFrom clinical trials and diagnostics to in vitro fertilization and cutting edge immunotherapies, CryoPort Express offers reliability and integrity for biologicals through its innovative technologies and solutions. I look forward to working with Larry and his team to implement a new industry standard.a

Prior to becoming a Technical Advisor, Dr. Bishara had a career of 35 years with Eli Lilly and Company, including as Director, Quality Knowledge Management and Technical Support. He previously served on the board of directors of Sensitech, Inc., and serves as a Temporary Advisor to the World Health Organization. He has authored numerous articles on cold chain and temperature-control management, and in 2007 received the Distinguished Service Award from the Parenteral Drug Association.

Dr. Bishara received his Master of Science Degree in Phytochemistry from Butler University and his Doctorate in Bionucleonics from Purdue University.

About CryoPort, Inc.

CryoPort ([ www.cryoport.com ]) has developed a leading edge, proprietary, technology-driven transport and packaging system focused on providing a solution that replaces dry ice for the frozen shipping market in the growing global life science industry. The products developed by CryoPort have a 10+ day holding time, are using agreena materials and are essential components of the infrastructure required for the testing, research and end-user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex global logistical environment.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding CryoPort, Inc.a™s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The companya™s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2011. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. CryoPort, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.